nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—CYP1A2—type 2 diabetes mellitus	0.477	1	CbGaD
Anagrelide—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.0678	0.329	CbGbCtD
Anagrelide—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.0534	0.259	CbGbCtD
Anagrelide—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.0505	0.245	CbGbCtD
Anagrelide—CYP1A2—Losartan—type 2 diabetes mellitus	0.0344	0.167	CbGbCtD
Anagrelide—PDE3A—penis—type 2 diabetes mellitus	0.00424	0.692	CbGeAlD
Anagrelide—PDE3A—cardiovascular system—type 2 diabetes mellitus	0.000682	0.111	CbGeAlD
Anagrelide—PDE3A—adipose tissue—type 2 diabetes mellitus	0.000601	0.0981	CbGeAlD
Anagrelide—PDE3A—liver—type 2 diabetes mellitus	0.000422	0.0688	CbGeAlD
Anagrelide—CYP1A2—liver—type 2 diabetes mellitus	0.000187	0.0305	CbGeAlD
Anagrelide—Ill-defined disorder—Losartan—type 2 diabetes mellitus	0.00013	0.000492	CcSEcCtD
Anagrelide—Cough—Irbesartan—type 2 diabetes mellitus	0.00013	0.000492	CcSEcCtD
Anagrelide—Headache—Sitagliptin—type 2 diabetes mellitus	0.00013	0.000491	CcSEcCtD
Anagrelide—Anaemia—Losartan—type 2 diabetes mellitus	0.00013	0.00049	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000129	0.000487	CcSEcCtD
Anagrelide—Oedema—Metformin—type 2 diabetes mellitus	0.000129	0.000487	CcSEcCtD
Anagrelide—Tinnitus—Ramipril—type 2 diabetes mellitus	0.000129	0.000487	CcSEcCtD
Anagrelide—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000129	0.000486	CcSEcCtD
Anagrelide—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000128	0.000485	CcSEcCtD
Anagrelide—Infection—Metformin—type 2 diabetes mellitus	0.000128	0.000484	CcSEcCtD
Anagrelide—Insomnia—Valsartan—type 2 diabetes mellitus	0.000128	0.000484	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000127	0.000482	CcSEcCtD
Anagrelide—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000127	0.00048	CcSEcCtD
Anagrelide—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000127	0.00048	CcSEcCtD
Anagrelide—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000127	0.00048	CcSEcCtD
Anagrelide—Myalgia—Irbesartan—type 2 diabetes mellitus	0.000127	0.00048	CcSEcCtD
Anagrelide—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000127	0.00048	CcSEcCtD
Anagrelide—Shock—Metformin—type 2 diabetes mellitus	0.000127	0.000479	CcSEcCtD
Anagrelide—Insomnia—Orlistat—type 2 diabetes mellitus	0.000126	0.000478	CcSEcCtD
Anagrelide—Malaise—Losartan—type 2 diabetes mellitus	0.000126	0.000478	CcSEcCtD
Anagrelide—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000126	0.000478	CcSEcCtD
Anagrelide—Thrombocytopenia—Metformin—type 2 diabetes mellitus	0.000126	0.000477	CcSEcCtD
Anagrelide—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000126	0.000477	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000126	0.000476	CcSEcCtD
Anagrelide—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000126	0.000476	CcSEcCtD
Anagrelide—Somnolence—Valsartan—type 2 diabetes mellitus	0.000126	0.000476	CcSEcCtD
Anagrelide—Syncope—Losartan—type 2 diabetes mellitus	0.000126	0.000475	CcSEcCtD
Anagrelide—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000125	0.000475	CcSEcCtD
Anagrelide—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000125	0.000474	CcSEcCtD
Anagrelide—Skin disorder—Metformin—type 2 diabetes mellitus	0.000125	0.000473	CcSEcCtD
Anagrelide—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000124	0.000471	CcSEcCtD
Anagrelide—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000124	0.000471	CcSEcCtD
Anagrelide—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000124	0.000471	CcSEcCtD
Anagrelide—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000124	0.000469	CcSEcCtD
Anagrelide—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000124	0.000469	CcSEcCtD
Anagrelide—Palpitations—Losartan—type 2 diabetes mellitus	0.000124	0.000469	CcSEcCtD
Anagrelide—Nausea—Glimepiride—type 2 diabetes mellitus	0.000123	0.000467	CcSEcCtD
Anagrelide—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.000123	0.000467	CcSEcCtD
Anagrelide—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000123	0.000466	CcSEcCtD
Anagrelide—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000123	0.000466	CcSEcCtD
Anagrelide—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000123	0.000465	CcSEcCtD
Anagrelide—Asthenia—Glyburide—type 2 diabetes mellitus	0.000123	0.000465	CcSEcCtD
Anagrelide—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000123	0.000465	CcSEcCtD
Anagrelide—Anorexia—Metformin—type 2 diabetes mellitus	0.000123	0.000464	CcSEcCtD
Anagrelide—Cough—Losartan—type 2 diabetes mellitus	0.000122	0.000463	CcSEcCtD
Anagrelide—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000122	0.000463	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000122	0.000462	CcSEcCtD
Anagrelide—Alopecia—Ramipril—type 2 diabetes mellitus	0.000122	0.000462	CcSEcCtD
Anagrelide—Fatigue—Valsartan—type 2 diabetes mellitus	0.000122	0.000461	CcSEcCtD
Anagrelide—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000122	0.00046	CcSEcCtD
Anagrelide—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000122	0.00046	CcSEcCtD
Anagrelide—Oedema—Irbesartan—type 2 diabetes mellitus	0.000122	0.00046	CcSEcCtD
Anagrelide—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000121	0.00046	CcSEcCtD
Anagrelide—Pruritus—Glyburide—type 2 diabetes mellitus	0.000121	0.000459	CcSEcCtD
Anagrelide—Constipation—Valsartan—type 2 diabetes mellitus	0.000121	0.000458	CcSEcCtD
Anagrelide—Infection—Irbesartan—type 2 diabetes mellitus	0.000121	0.000457	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000121	0.000456	CcSEcCtD
Anagrelide—Fatigue—Orlistat—type 2 diabetes mellitus	0.00012	0.000456	CcSEcCtD
Anagrelide—Hypotension—Metformin—type 2 diabetes mellitus	0.00012	0.000455	CcSEcCtD
Anagrelide—Malnutrition—Ramipril—type 2 diabetes mellitus	0.00012	0.000455	CcSEcCtD
Anagrelide—Shock—Irbesartan—type 2 diabetes mellitus	0.00012	0.000452	CcSEcCtD
Anagrelide—Pain—Orlistat—type 2 diabetes mellitus	0.000119	0.000452	CcSEcCtD
Anagrelide—Myalgia—Losartan—type 2 diabetes mellitus	0.000119	0.000451	CcSEcCtD
Anagrelide—Chest pain—Losartan—type 2 diabetes mellitus	0.000119	0.000451	CcSEcCtD
Anagrelide—Arthralgia—Losartan—type 2 diabetes mellitus	0.000119	0.000451	CcSEcCtD
Anagrelide—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000119	0.000451	CcSEcCtD
Anagrelide—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000119	0.000451	CcSEcCtD
Anagrelide—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	0.000119	0.00045	CcSEcCtD
Anagrelide—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000119	0.000449	CcSEcCtD
Anagrelide—Rash—Bromocriptine—type 2 diabetes mellitus	0.000118	0.000447	CcSEcCtD
Anagrelide—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000118	0.000447	CcSEcCtD
Anagrelide—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000118	0.000447	CcSEcCtD
Anagrelide—Tension—Ramipril—type 2 diabetes mellitus	0.000118	0.000446	CcSEcCtD
Anagrelide—Discomfort—Losartan—type 2 diabetes mellitus	0.000118	0.000446	CcSEcCtD
Anagrelide—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000117	0.000445	CcSEcCtD
Anagrelide—Headache—Bromocriptine—type 2 diabetes mellitus	0.000117	0.000444	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000117	0.000444	CcSEcCtD
Anagrelide—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000117	0.000444	CcSEcCtD
Anagrelide—Nervousness—Ramipril—type 2 diabetes mellitus	0.000117	0.000442	CcSEcCtD
Anagrelide—Dry mouth—Losartan—type 2 diabetes mellitus	0.000117	0.000441	CcSEcCtD
Anagrelide—Anorexia—Irbesartan—type 2 diabetes mellitus	0.000116	0.000438	CcSEcCtD
Anagrelide—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000116	0.000438	CcSEcCtD
Anagrelide—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000116	0.000438	CcSEcCtD
Anagrelide—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.000116	0.000437	CcSEcCtD
Anagrelide—Confusional state—Losartan—type 2 diabetes mellitus	0.000115	0.000436	CcSEcCtD
Anagrelide—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000115	0.000436	CcSEcCtD
Anagrelide—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000115	0.000434	CcSEcCtD
Anagrelide—Somnolence—Metformin—type 2 diabetes mellitus	0.000114	0.000433	CcSEcCtD
Anagrelide—Oedema—Losartan—type 2 diabetes mellitus	0.000114	0.000433	CcSEcCtD
Anagrelide—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000114	0.000432	CcSEcCtD
Anagrelide—Infection—Losartan—type 2 diabetes mellitus	0.000114	0.00043	CcSEcCtD
Anagrelide—Hypotension—Irbesartan—type 2 diabetes mellitus	0.000114	0.00043	CcSEcCtD
Anagrelide—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000113	0.000429	CcSEcCtD
Anagrelide—Shock—Losartan—type 2 diabetes mellitus	0.000113	0.000426	CcSEcCtD
Anagrelide—Urticaria—Valsartan—type 2 diabetes mellitus	0.000112	0.000425	CcSEcCtD
Anagrelide—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000112	0.000424	CcSEcCtD
Anagrelide—Thrombocytopenia—Losartan—type 2 diabetes mellitus	0.000112	0.000424	CcSEcCtD
Anagrelide—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000112	0.000424	CcSEcCtD
Anagrelide—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000112	0.000423	CcSEcCtD
Anagrelide—Tachycardia—Losartan—type 2 diabetes mellitus	0.000112	0.000422	CcSEcCtD
Anagrelide—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	0.000111	0.000422	CcSEcCtD
Anagrelide—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000111	0.000421	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000111	0.000421	CcSEcCtD
Anagrelide—Fatigue—Metformin—type 2 diabetes mellitus	0.000111	0.00042	CcSEcCtD
Anagrelide—Urticaria—Orlistat—type 2 diabetes mellitus	0.000111	0.00042	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000111	0.000419	CcSEcCtD
Anagrelide—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.000111	0.000418	CcSEcCtD
Anagrelide—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.00011	0.000418	CcSEcCtD
Anagrelide—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.00011	0.000418	CcSEcCtD
Anagrelide—Asthenia—Gliclazide—type 2 diabetes mellitus	0.00011	0.000418	CcSEcCtD
Anagrelide—Constipation—Metformin—type 2 diabetes mellitus	0.00011	0.000417	CcSEcCtD
Anagrelide—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.000109	0.000413	CcSEcCtD
Anagrelide—Anorexia—Losartan—type 2 diabetes mellitus	0.000109	0.000412	CcSEcCtD
Anagrelide—Vomiting—Glyburide—type 2 diabetes mellitus	0.000109	0.000412	CcSEcCtD
Anagrelide—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000109	0.000412	CcSEcCtD
Anagrelide—Malaise—Ramipril—type 2 diabetes mellitus	0.000108	0.00041	CcSEcCtD
Anagrelide—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000108	0.00041	CcSEcCtD
Anagrelide—Rash—Glyburide—type 2 diabetes mellitus	0.000108	0.000409	CcSEcCtD
Anagrelide—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000108	0.000409	CcSEcCtD
Anagrelide—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000108	0.000409	CcSEcCtD
Anagrelide—Syncope—Ramipril—type 2 diabetes mellitus	0.000108	0.000408	CcSEcCtD
Anagrelide—Headache—Glyburide—type 2 diabetes mellitus	0.000107	0.000406	CcSEcCtD
Anagrelide—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000107	0.000405	CcSEcCtD
Anagrelide—Hypotension—Losartan—type 2 diabetes mellitus	0.000107	0.000404	CcSEcCtD
Anagrelide—Palpitations—Ramipril—type 2 diabetes mellitus	0.000106	0.000402	CcSEcCtD
Anagrelide—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000106	0.000402	CcSEcCtD
Anagrelide—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000106	0.0004	CcSEcCtD
Anagrelide—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.000106	0.0004	CcSEcCtD
Anagrelide—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000105	0.000398	CcSEcCtD
Anagrelide—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000105	0.000398	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000105	0.000397	CcSEcCtD
Anagrelide—Cough—Ramipril—type 2 diabetes mellitus	0.000105	0.000397	CcSEcCtD
Anagrelide—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000105	0.000396	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000104	0.000394	CcSEcCtD
Anagrelide—Convulsion—Ramipril—type 2 diabetes mellitus	0.000104	0.000394	CcSEcCtD
Anagrelide—Pain—Irbesartan—type 2 diabetes mellitus	0.000104	0.000393	CcSEcCtD
Anagrelide—Constipation—Irbesartan—type 2 diabetes mellitus	0.000104	0.000393	CcSEcCtD
Anagrelide—Insomnia—Losartan—type 2 diabetes mellitus	0.000103	0.000391	CcSEcCtD
Anagrelide—Paraesthesia—Losartan—type 2 diabetes mellitus	0.000103	0.000389	CcSEcCtD
Anagrelide—Urticaria—Metformin—type 2 diabetes mellitus	0.000102	0.000387	CcSEcCtD
Anagrelide—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000102	0.000387	CcSEcCtD
Anagrelide—Myalgia—Ramipril—type 2 diabetes mellitus	0.000102	0.000387	CcSEcCtD
Anagrelide—Chest pain—Ramipril—type 2 diabetes mellitus	0.000102	0.000387	CcSEcCtD
Anagrelide—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000102	0.000386	CcSEcCtD
Anagrelide—Nausea—Glyburide—type 2 diabetes mellitus	0.000102	0.000385	CcSEcCtD
Anagrelide—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000102	0.000385	CcSEcCtD
Anagrelide—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000102	0.000385	CcSEcCtD
Anagrelide—Somnolence—Losartan—type 2 diabetes mellitus	0.000102	0.000385	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000102	0.000384	CcSEcCtD
Anagrelide—Asthenia—Valsartan—type 2 diabetes mellitus	0.000101	0.000384	CcSEcCtD
Anagrelide—Discomfort—Ramipril—type 2 diabetes mellitus	0.000101	0.000382	CcSEcCtD
Anagrelide—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000101	0.000381	CcSEcCtD
Anagrelide—Asthenia—Orlistat—type 2 diabetes mellitus	0.0001	0.000379	CcSEcCtD
Anagrelide—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.0001	0.000379	CcSEcCtD
Anagrelide—Pruritus—Valsartan—type 2 diabetes mellitus	0.0001	0.000379	CcSEcCtD
Anagrelide—Dry mouth—Ramipril—type 2 diabetes mellitus	0.0001	0.000379	CcSEcCtD
Anagrelide—Decreased appetite—Losartan—type 2 diabetes mellitus	9.94e-05	0.000376	CcSEcCtD
Anagrelide—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	9.94e-05	0.000376	CcSEcCtD
Anagrelide—Confusional state—Ramipril—type 2 diabetes mellitus	9.89e-05	0.000374	CcSEcCtD
Anagrelide—Pruritus—Orlistat—type 2 diabetes mellitus	9.88e-05	0.000374	CcSEcCtD
Anagrelide—Fatigue—Losartan—type 2 diabetes mellitus	9.86e-05	0.000373	CcSEcCtD
Anagrelide—Oedema—Ramipril—type 2 diabetes mellitus	9.81e-05	0.000371	CcSEcCtD
Anagrelide—Vomiting—Gliclazide—type 2 diabetes mellitus	9.79e-05	0.00037	CcSEcCtD
Anagrelide—Pain—Losartan—type 2 diabetes mellitus	9.78e-05	0.00037	CcSEcCtD
Anagrelide—Constipation—Losartan—type 2 diabetes mellitus	9.78e-05	0.00037	CcSEcCtD
Anagrelide—Rash—Gliclazide—type 2 diabetes mellitus	9.7e-05	0.000367	CcSEcCtD
Anagrelide—Dermatitis—Gliclazide—type 2 diabetes mellitus	9.69e-05	0.000367	CcSEcCtD
Anagrelide—Diarrhoea—Valsartan—type 2 diabetes mellitus	9.67e-05	0.000366	CcSEcCtD
Anagrelide—Urticaria—Irbesartan—type 2 diabetes mellitus	9.65e-05	0.000365	CcSEcCtD
Anagrelide—Shock—Ramipril—type 2 diabetes mellitus	9.65e-05	0.000365	CcSEcCtD
Anagrelide—Headache—Gliclazide—type 2 diabetes mellitus	9.64e-05	0.000365	CcSEcCtD
Anagrelide—Nervous system disorder—Ramipril—type 2 diabetes mellitus	9.62e-05	0.000364	CcSEcCtD
Anagrelide—Abdominal pain—Irbesartan—type 2 diabetes mellitus	9.61e-05	0.000363	CcSEcCtD
Anagrelide—Body temperature increased—Irbesartan—type 2 diabetes mellitus	9.61e-05	0.000363	CcSEcCtD
Anagrelide—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	9.6e-05	0.000363	CcSEcCtD
Anagrelide—Tachycardia—Ramipril—type 2 diabetes mellitus	9.57e-05	0.000362	CcSEcCtD
Anagrelide—Diarrhoea—Orlistat—type 2 diabetes mellitus	9.56e-05	0.000362	CcSEcCtD
Anagrelide—Skin disorder—Ramipril—type 2 diabetes mellitus	9.52e-05	0.00036	CcSEcCtD
Anagrelide—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	9.48e-05	0.000359	CcSEcCtD
Anagrelide—Feeling abnormal—Losartan—type 2 diabetes mellitus	9.42e-05	0.000357	CcSEcCtD
Anagrelide—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	9.35e-05	0.000354	CcSEcCtD
Anagrelide—Dizziness—Valsartan—type 2 diabetes mellitus	9.35e-05	0.000354	CcSEcCtD
Anagrelide—Anorexia—Ramipril—type 2 diabetes mellitus	9.35e-05	0.000354	CcSEcCtD
Anagrelide—Dizziness—Orlistat—type 2 diabetes mellitus	9.24e-05	0.00035	CcSEcCtD
Anagrelide—Asthenia—Metformin—type 2 diabetes mellitus	9.24e-05	0.00035	CcSEcCtD
Anagrelide—Hypotension—Ramipril—type 2 diabetes mellitus	9.16e-05	0.000347	CcSEcCtD
Anagrelide—Nausea—Gliclazide—type 2 diabetes mellitus	9.14e-05	0.000346	CcSEcCtD
Anagrelide—Pruritus—Metformin—type 2 diabetes mellitus	9.11e-05	0.000345	CcSEcCtD
Anagrelide—Urticaria—Losartan—type 2 diabetes mellitus	9.08e-05	0.000344	CcSEcCtD
Anagrelide—Body temperature increased—Losartan—type 2 diabetes mellitus	9.04e-05	0.000342	CcSEcCtD
Anagrelide—Abdominal pain—Losartan—type 2 diabetes mellitus	9.04e-05	0.000342	CcSEcCtD
Anagrelide—Vomiting—Valsartan—type 2 diabetes mellitus	8.99e-05	0.00034	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	8.93e-05	0.000338	CcSEcCtD
Anagrelide—Rash—Valsartan—type 2 diabetes mellitus	8.92e-05	0.000337	CcSEcCtD
Anagrelide—Dermatitis—Valsartan—type 2 diabetes mellitus	8.91e-05	0.000337	CcSEcCtD
Anagrelide—Vomiting—Orlistat—type 2 diabetes mellitus	8.88e-05	0.000336	CcSEcCtD
Anagrelide—Insomnia—Ramipril—type 2 diabetes mellitus	8.87e-05	0.000336	CcSEcCtD
Anagrelide—Headache—Valsartan—type 2 diabetes mellitus	8.86e-05	0.000335	CcSEcCtD
Anagrelide—Diarrhoea—Metformin—type 2 diabetes mellitus	8.81e-05	0.000333	CcSEcCtD
Anagrelide—Rash—Orlistat—type 2 diabetes mellitus	8.81e-05	0.000333	CcSEcCtD
Anagrelide—Paraesthesia—Ramipril—type 2 diabetes mellitus	8.8e-05	0.000333	CcSEcCtD
Anagrelide—Dermatitis—Orlistat—type 2 diabetes mellitus	8.8e-05	0.000333	CcSEcCtD
Anagrelide—Headache—Orlistat—type 2 diabetes mellitus	8.75e-05	0.000331	CcSEcCtD
Anagrelide—Dyspnoea—Ramipril—type 2 diabetes mellitus	8.74e-05	0.000331	CcSEcCtD
Anagrelide—Asthenia—Irbesartan—type 2 diabetes mellitus	8.72e-05	0.00033	CcSEcCtD
Anagrelide—Somnolence—Ramipril—type 2 diabetes mellitus	8.72e-05	0.00033	CcSEcCtD
Anagrelide—Dyspepsia—Ramipril—type 2 diabetes mellitus	8.63e-05	0.000327	CcSEcCtD
Anagrelide—Pruritus—Irbesartan—type 2 diabetes mellitus	8.6e-05	0.000325	CcSEcCtD
Anagrelide—Decreased appetite—Ramipril—type 2 diabetes mellitus	8.52e-05	0.000323	CcSEcCtD
Anagrelide—Dizziness—Metformin—type 2 diabetes mellitus	8.51e-05	0.000322	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	8.47e-05	0.00032	CcSEcCtD
Anagrelide—Fatigue—Ramipril—type 2 diabetes mellitus	8.45e-05	0.00032	CcSEcCtD
Anagrelide—Nausea—Valsartan—type 2 diabetes mellitus	8.4e-05	0.000318	CcSEcCtD
Anagrelide—Constipation—Ramipril—type 2 diabetes mellitus	8.39e-05	0.000317	CcSEcCtD
Anagrelide—Diarrhoea—Irbesartan—type 2 diabetes mellitus	8.31e-05	0.000315	CcSEcCtD
Anagrelide—Nausea—Orlistat—type 2 diabetes mellitus	8.3e-05	0.000314	CcSEcCtD
Anagrelide—Asthenia—Losartan—type 2 diabetes mellitus	8.2e-05	0.00031	CcSEcCtD
Anagrelide—Vomiting—Metformin—type 2 diabetes mellitus	8.19e-05	0.00031	CcSEcCtD
Anagrelide—Rash—Metformin—type 2 diabetes mellitus	8.12e-05	0.000307	CcSEcCtD
Anagrelide—Dermatitis—Metformin—type 2 diabetes mellitus	8.11e-05	0.000307	CcSEcCtD
Anagrelide—Pruritus—Losartan—type 2 diabetes mellitus	8.09e-05	0.000306	CcSEcCtD
Anagrelide—Feeling abnormal—Ramipril—type 2 diabetes mellitus	8.08e-05	0.000306	CcSEcCtD
Anagrelide—Headache—Metformin—type 2 diabetes mellitus	8.07e-05	0.000305	CcSEcCtD
Anagrelide—Dizziness—Irbesartan—type 2 diabetes mellitus	8.04e-05	0.000304	CcSEcCtD
Anagrelide—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	8.02e-05	0.000303	CcSEcCtD
Anagrelide—Diarrhoea—Losartan—type 2 diabetes mellitus	7.82e-05	0.000296	CcSEcCtD
Anagrelide—Urticaria—Ramipril—type 2 diabetes mellitus	7.79e-05	0.000295	CcSEcCtD
Anagrelide—Body temperature increased—Ramipril—type 2 diabetes mellitus	7.75e-05	0.000293	CcSEcCtD
Anagrelide—Abdominal pain—Ramipril—type 2 diabetes mellitus	7.75e-05	0.000293	CcSEcCtD
Anagrelide—Vomiting—Irbesartan—type 2 diabetes mellitus	7.73e-05	0.000292	CcSEcCtD
Anagrelide—Rash—Irbesartan—type 2 diabetes mellitus	7.66e-05	0.00029	CcSEcCtD
Anagrelide—Dermatitis—Irbesartan—type 2 diabetes mellitus	7.65e-05	0.00029	CcSEcCtD
Anagrelide—Nausea—Metformin—type 2 diabetes mellitus	7.65e-05	0.000289	CcSEcCtD
Anagrelide—Headache—Irbesartan—type 2 diabetes mellitus	7.61e-05	0.000288	CcSEcCtD
Anagrelide—Dizziness—Losartan—type 2 diabetes mellitus	7.56e-05	0.000286	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—MTR—type 2 diabetes mellitus	7.44e-05	0.00161	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—EDNRA—type 2 diabetes mellitus	7.43e-05	0.00161	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LEPR—type 2 diabetes mellitus	7.32e-05	0.00159	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—type 2 diabetes mellitus	7.3e-05	0.00158	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—GCG—type 2 diabetes mellitus	7.29e-05	0.00158	CbGpPWpGaD
Anagrelide—Vomiting—Losartan—type 2 diabetes mellitus	7.27e-05	0.000275	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—ADRA2A—type 2 diabetes mellitus	7.27e-05	0.00157	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—GHRL—type 2 diabetes mellitus	7.24e-05	0.00157	CbGpPWpGaD
Anagrelide—Nausea—Irbesartan—type 2 diabetes mellitus	7.22e-05	0.000273	CcSEcCtD
Anagrelide—Rash—Losartan—type 2 diabetes mellitus	7.21e-05	0.000273	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—CYP11A1—type 2 diabetes mellitus	7.21e-05	0.00156	CbGpPWpGaD
Anagrelide—Dermatitis—Losartan—type 2 diabetes mellitus	7.2e-05	0.000273	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—RASGRP1—type 2 diabetes mellitus	7.17e-05	0.00155	CbGpPWpGaD
Anagrelide—Headache—Losartan—type 2 diabetes mellitus	7.16e-05	0.000271	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—PRKCB—type 2 diabetes mellitus	7.15e-05	0.00155	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CALCA—type 2 diabetes mellitus	7.15e-05	0.00155	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP11A1—type 2 diabetes mellitus	7.11e-05	0.00154	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—NOS2—type 2 diabetes mellitus	7.07e-05	0.00153	CbGpPWpGaD
Anagrelide—Asthenia—Ramipril—type 2 diabetes mellitus	7.04e-05	0.000266	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—ATP2A3—type 2 diabetes mellitus	7e-05	0.00152	CbGpPWpGaD
Anagrelide—Pruritus—Ramipril—type 2 diabetes mellitus	6.94e-05	0.000263	CcSEcCtD
Anagrelide—CYP1A2—Arachidonic acid metabolism—PTGS2—type 2 diabetes mellitus	6.83e-05	0.00148	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TLE4—type 2 diabetes mellitus	6.81e-05	0.00147	CbGpPWpGaD
Anagrelide—Nausea—Losartan—type 2 diabetes mellitus	6.79e-05	0.000257	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTGDS—type 2 diabetes mellitus	6.75e-05	0.00146	CbGpPWpGaD
Anagrelide—Diarrhoea—Ramipril—type 2 diabetes mellitus	6.71e-05	0.000254	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—GCG—type 2 diabetes mellitus	6.62e-05	0.00143	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADRB3—type 2 diabetes mellitus	6.55e-05	0.00142	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—RASGRP1—type 2 diabetes mellitus	6.51e-05	0.00141	CbGpPWpGaD
Anagrelide—Dizziness—Ramipril—type 2 diabetes mellitus	6.48e-05	0.000245	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—GPD2—type 2 diabetes mellitus	6.4e-05	0.00139	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—type 2 diabetes mellitus	6.34e-05	0.00137	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CRHR1—type 2 diabetes mellitus	6.33e-05	0.00137	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—GNB3—type 2 diabetes mellitus	6.28e-05	0.00136	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IGF1—type 2 diabetes mellitus	6.27e-05	0.00136	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—AKT2—type 2 diabetes mellitus	6.26e-05	0.00136	CbGpPWpGaD
Anagrelide—Vomiting—Ramipril—type 2 diabetes mellitus	6.23e-05	0.000236	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—AVP—type 2 diabetes mellitus	6.2e-05	0.00134	CbGpPWpGaD
Anagrelide—Rash—Ramipril—type 2 diabetes mellitus	6.18e-05	0.000234	CcSEcCtD
Anagrelide—Dermatitis—Ramipril—type 2 diabetes mellitus	6.18e-05	0.000234	CcSEcCtD
Anagrelide—Headache—Ramipril—type 2 diabetes mellitus	6.14e-05	0.000232	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—SERPINE1—type 2 diabetes mellitus	5.95e-05	0.00129	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP2E1—type 2 diabetes mellitus	5.95e-05	0.00129	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—ALB—type 2 diabetes mellitus	5.94e-05	0.00129	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—SRC—type 2 diabetes mellitus	5.9e-05	0.00128	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—type 2 diabetes mellitus	5.9e-05	0.00128	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	5.89e-05	0.00128	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP2E1—type 2 diabetes mellitus	5.87e-05	0.00127	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	5.84e-05	0.00127	CbGpPWpGaD
Anagrelide—Nausea—Ramipril—type 2 diabetes mellitus	5.82e-05	0.00022	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—SPRY2—type 2 diabetes mellitus	5.79e-05	0.00125	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	5.79e-05	0.00125	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—type 2 diabetes mellitus	5.75e-05	0.00125	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP3A4—type 2 diabetes mellitus	5.74e-05	0.00124	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—GNB3—type 2 diabetes mellitus	5.7e-05	0.00124	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3R1—type 2 diabetes mellitus	5.68e-05	0.00123	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—NOS3—type 2 diabetes mellitus	5.68e-05	0.00123	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP3A4—type 2 diabetes mellitus	5.66e-05	0.00123	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RBP4—type 2 diabetes mellitus	5.64e-05	0.00122	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GLP1R—type 2 diabetes mellitus	5.64e-05	0.00122	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AVP—type 2 diabetes mellitus	5.63e-05	0.00122	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—MMP3—type 2 diabetes mellitus	5.63e-05	0.00122	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	5.6e-05	0.00121	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCKAR—type 2 diabetes mellitus	5.55e-05	0.0012	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—EDN1—type 2 diabetes mellitus	5.35e-05	0.00116	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—type 2 diabetes mellitus	5.28e-05	0.00114	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	5.27e-05	0.00114	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—type 2 diabetes mellitus	5.18e-05	0.00112	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—type 2 diabetes mellitus	5.18e-05	0.00112	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—C3—type 2 diabetes mellitus	5.15e-05	0.00112	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	5.08e-05	0.0011	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	5.03e-05	0.00109	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IAPP—type 2 diabetes mellitus	5e-05	0.00108	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—OXCT1—type 2 diabetes mellitus	4.98e-05	0.00108	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—INSR—type 2 diabetes mellitus	4.97e-05	0.00108	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—type 2 diabetes mellitus	4.93e-05	0.00107	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—type 2 diabetes mellitus	4.93e-05	0.00107	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AGT—type 2 diabetes mellitus	4.89e-05	0.00106	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TRPC6—type 2 diabetes mellitus	4.88e-05	0.00106	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	4.87e-05	0.00106	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AGTR2—type 2 diabetes mellitus	4.85e-05	0.00105	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—SRD5A1—type 2 diabetes mellitus	4.85e-05	0.00105	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCR5—type 2 diabetes mellitus	4.79e-05	0.00104	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—C3—type 2 diabetes mellitus	4.68e-05	0.00101	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EDNRB—type 2 diabetes mellitus	4.65e-05	0.00101	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B3—type 2 diabetes mellitus	4.63e-05	0.001	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ACACA—type 2 diabetes mellitus	4.63e-05	0.001	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—STAR—type 2 diabetes mellitus	4.63e-05	0.001	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	4.52e-05	0.000979	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PSMD6—type 2 diabetes mellitus	4.51e-05	0.000977	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HTR2C—type 2 diabetes mellitus	4.51e-05	0.000977	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTM1—type 2 diabetes mellitus	4.51e-05	0.000977	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTM1—type 2 diabetes mellitus	4.45e-05	0.000963	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AGT—type 2 diabetes mellitus	4.44e-05	0.000963	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EDNRA—type 2 diabetes mellitus	4.39e-05	0.00095	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CALM1—type 2 diabetes mellitus	4.37e-05	0.000946	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CYBA—type 2 diabetes mellitus	4.37e-05	0.000946	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	4.29e-05	0.00093	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GHRL—type 2 diabetes mellitus	4.28e-05	0.000926	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PLAT—type 2 diabetes mellitus	4.28e-05	0.000926	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CALCA—type 2 diabetes mellitus	4.22e-05	0.000915	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—SRC—type 2 diabetes mellitus	4.2e-05	0.000911	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—NCOA6—type 2 diabetes mellitus	4.19e-05	0.000908	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HSD11B1—type 2 diabetes mellitus	4.12e-05	0.000893	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	4.11e-05	0.000889	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—VEGFA—type 2 diabetes mellitus	4.09e-05	0.000887	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	3.98e-05	0.000862	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	3.96e-05	0.000858	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	3.91e-05	0.000847	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GCG—type 2 diabetes mellitus	3.91e-05	0.000847	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	3.85e-05	0.000833	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	3.83e-05	0.000831	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TGFB1—type 2 diabetes mellitus	3.76e-05	0.000814	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	3.66e-05	0.000793	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	3.59e-05	0.000779	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	3.59e-05	0.000778	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HSD3B2—type 2 diabetes mellitus	3.51e-05	0.000759	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LPA—type 2 diabetes mellitus	3.51e-05	0.000759	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—BHMT—type 2 diabetes mellitus	3.44e-05	0.000745	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	3.4e-05	0.000737	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GNB3—type 2 diabetes mellitus	3.37e-05	0.00073	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MMP3—type 2 diabetes mellitus	3.32e-05	0.00072	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AVP—type 2 diabetes mellitus	3.32e-05	0.00072	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IGF2—type 2 diabetes mellitus	3.31e-05	0.000717	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	3.3e-05	0.000714	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	3.26e-05	0.000707	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APOB—type 2 diabetes mellitus	3.21e-05	0.000696	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	3.2e-05	0.000693	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EDN1—type 2 diabetes mellitus	3.16e-05	0.000685	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LPL—type 2 diabetes mellitus	3.07e-05	0.000665	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGDS—type 2 diabetes mellitus	3.01e-05	0.000651	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AANAT—type 2 diabetes mellitus	3.01e-05	0.000651	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	3e-05	0.000651	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	2.88e-05	0.000624	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CPT1A—type 2 diabetes mellitus	2.86e-05	0.000619	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GPD2—type 2 diabetes mellitus	2.85e-05	0.000617	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CDO1—type 2 diabetes mellitus	2.85e-05	0.000617	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCR5—type 2 diabetes mellitus	2.83e-05	0.000612	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—type 2 diabetes mellitus	2.79e-05	0.000603	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—type 2 diabetes mellitus	2.77e-05	0.0006	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—C3—type 2 diabetes mellitus	2.76e-05	0.000598	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AK1—type 2 diabetes mellitus	2.72e-05	0.000589	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CETP—type 2 diabetes mellitus	2.69e-05	0.000582	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.63e-05	0.000571	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.63e-05	0.000569	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AGT—type 2 diabetes mellitus	2.62e-05	0.000569	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—AKT1—type 2 diabetes mellitus	2.61e-05	0.000566	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.58e-05	0.000559	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LEP—type 2 diabetes mellitus	2.57e-05	0.000557	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APOE—type 2 diabetes mellitus	2.57e-05	0.000557	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.54e-05	0.000551	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC5A4—type 2 diabetes mellitus	2.51e-05	0.000543	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MAT1A—type 2 diabetes mellitus	2.51e-05	0.000543	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—SREBF1—type 2 diabetes mellitus	2.5e-05	0.000541	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—type 2 diabetes mellitus	2.45e-05	0.000531	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HMGCR—type 2 diabetes mellitus	2.43e-05	0.000526	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.43e-05	0.000525	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ND1—type 2 diabetes mellitus	2.42e-05	0.000525	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—G6PC—type 2 diabetes mellitus	2.42e-05	0.000525	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ENPP1—type 2 diabetes mellitus	2.42e-05	0.000525	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HBA2—type 2 diabetes mellitus	2.42e-05	0.000525	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPP1R3C—type 2 diabetes mellitus	2.42e-05	0.000525	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GCGR—type 2 diabetes mellitus	2.35e-05	0.000508	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.29e-05	0.000497	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—OXCT1—type 2 diabetes mellitus	2.22e-05	0.00048	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYTB—type 2 diabetes mellitus	2.22e-05	0.00048	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—INS—type 2 diabetes mellitus	2.2e-05	0.000476	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.16e-05	0.000468	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SRD5A1—type 2 diabetes mellitus	2.16e-05	0.000468	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.13e-05	0.00046	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.12e-05	0.00046	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.11e-05	0.000458	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HSD17B3—type 2 diabetes mellitus	2.06e-05	0.000446	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—STAR—type 2 diabetes mellitus	2.06e-05	0.000446	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ACACA—type 2 diabetes mellitus	2.06e-05	0.000446	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.02e-05	0.000437	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCC8—type 2 diabetes mellitus	1.98e-05	0.000428	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CBS—type 2 diabetes mellitus	1.98e-05	0.000428	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.93e-05	0.000417	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.93e-05	0.000417	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—COX2—type 2 diabetes mellitus	1.9e-05	0.000412	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC5A2—type 2 diabetes mellitus	1.9e-05	0.000412	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NCOA6—type 2 diabetes mellitus	1.87e-05	0.000405	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PPARGC1A—type 2 diabetes mellitus	1.87e-05	0.000404	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—UCP3—type 2 diabetes mellitus	1.84e-05	0.000398	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—UCP2—type 2 diabetes mellitus	1.84e-05	0.000398	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HSD11B1—type 2 diabetes mellitus	1.84e-05	0.000398	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.81e-05	0.000393	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOB—type 2 diabetes mellitus	1.78e-05	0.000386	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PCK1—type 2 diabetes mellitus	1.73e-05	0.000374	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LPL—type 2 diabetes mellitus	1.7e-05	0.000368	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—type 2 diabetes mellitus	1.66e-05	0.000359	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.65e-05	0.000358	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.64e-05	0.000354	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.63e-05	0.000352	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HK1—type 2 diabetes mellitus	1.62e-05	0.00035	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CD36—type 2 diabetes mellitus	1.61e-05	0.00035	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—KCNJ11—type 2 diabetes mellitus	1.56e-05	0.000338	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LPA—type 2 diabetes mellitus	1.56e-05	0.000338	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GCKR—type 2 diabetes mellitus	1.56e-05	0.000338	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HSD3B2—type 2 diabetes mellitus	1.56e-05	0.000338	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.55e-05	0.000335	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.53e-05	0.000331	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—type 2 diabetes mellitus	1.5e-05	0.000325	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.5e-05	0.000325	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALDOB—type 2 diabetes mellitus	1.5e-05	0.000324	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—AGT—type 2 diabetes mellitus	1.45e-05	0.000315	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.43e-05	0.000309	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—type 2 diabetes mellitus	1.42e-05	0.000309	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	1.41e-05	0.000305	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GLP1R—type 2 diabetes mellitus	1.39e-05	0.000301	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.39e-05	0.000301	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC2A2—type 2 diabetes mellitus	1.3e-05	0.000281	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.27e-05	0.000276	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CPT1A—type 2 diabetes mellitus	1.27e-05	0.000276	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MTR—type 2 diabetes mellitus	1.27e-05	0.000276	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.25e-05	0.000271	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NAMPT—type 2 diabetes mellitus	1.25e-05	0.00027	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	1.24e-05	0.000269	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HBA1—type 2 diabetes mellitus	1.24e-05	0.000269	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LIPC—type 2 diabetes mellitus	1.24e-05	0.000269	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GCK—type 2 diabetes mellitus	1.24e-05	0.000269	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP11A1—type 2 diabetes mellitus	1.23e-05	0.000267	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC9A1—type 2 diabetes mellitus	1.21e-05	0.000262	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CETP—type 2 diabetes mellitus	1.2e-05	0.000259	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	1.12e-05	0.000242	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SNAP25—type 2 diabetes mellitus	1.11e-05	0.000241	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PSMD6—type 2 diabetes mellitus	1.11e-05	0.000241	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SREBF1—type 2 diabetes mellitus	1.11e-05	0.000241	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CTGF—type 2 diabetes mellitus	1.09e-05	0.000237	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HMGCR—type 2 diabetes mellitus	1.08e-05	0.000234	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	1.07e-05	0.000231	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ADRA2A—type 2 diabetes mellitus	1.06e-05	0.000229	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP2E1—type 2 diabetes mellitus	1.02e-05	0.00022	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC2A1—type 2 diabetes mellitus	1.01e-05	0.000218	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP3A4—type 2 diabetes mellitus	9.81e-06	0.000213	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	9.76e-06	0.000211	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	9.65e-06	0.000209	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	9.65e-06	0.000209	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6—type 2 diabetes mellitus	9.6e-06	0.000208	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.86e-06	0.000192	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	8.31e-06	0.00018	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	8.31e-06	0.00018	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	8.28e-06	0.000179	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	8.17e-06	0.000177	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	7.93e-06	0.000172	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	7.71e-06	0.000167	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	7.57e-06	0.000164	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	7.41e-06	0.000161	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	7.38e-06	0.00016	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	7.19e-06	0.000156	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	7.1e-06	0.000154	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	6.81e-06	0.000148	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	6.69e-06	0.000145	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	6.48e-06	0.00014	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	6.37e-06	0.000138	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	6.34e-06	0.000137	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	6.27e-06	0.000136	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	5.53e-06	0.00012	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	5.42e-06	0.000117	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	4.97e-06	0.000108	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	4.75e-06	0.000103	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	4.75e-06	0.000103	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	4.35e-06	9.42e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	2.18e-06	4.73e-05	CbGpPWpGaD
